ARTICLE | Clinical News
ALX-0681: Phase I data
August 24, 2009 7:00 AM UTC
Data from 36 healthy volunteers in a double-blind, placebo-controlled, single and multiple dose Phase I trial showed that daily injections of 10 mg ALX-0681 achieved complete inhibition of ristocetin...